| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514551000 | Z radical contains nitrogen | 44 |
| 20080242726 | Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol - Compositions comprising trans-clomiphene may be used in treating benign prostate hypertrophy, prostate cancer, elevated triglyceride levels and hypogonadism. | 10-02-2008 |
| 20080293813 | Compositions and Methods - Gaseous nitric oxide (NO) can be delivered to a mammal for prophylactic or therapeutic purposes using a composition capable of delivering NO, comprising a compound capable of forming a reversible bond or association with NO. Methods for the manufacture and use of said composition are disclosed. | 11-27-2008 |
| 20090093542 | Copper antagonist compositions - Pharmaceutical compositions having a pharmaceutically acceptable copper antagonist(s) or a pharmaceutically acceptable salts or prodrugs thereof, including copper (II) antagonists, and a pharmaceutically acceptable antihypertensive agent or a pharmaceutically acceptable salt or prodrug thereof, articles and kits and delivery devices containing compositions, tablets and capsules and formulations containing such compositions, and methods of use for treatment of subjects, including humans, who have or are at risk for various diseases, disorders, and conditions. | 04-09-2009 |
| 20090118368 | COMPOUNDS FOR INHIBITION OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE REUPTAKE OR FOR TREATMENT OF DEPRESSION DISORDERS, THEIR PREPARATION PROCESSES AND USES THEREOF - The present invention discloses compounds of formula (I), their optical isomers or pharmaceutically acceptable salts thereof, their preparation and uses thereof, wherein the definitions of R1, R2, R3 and R4 are shown in the description. These compounds are optical isomers or racemic mixtures. After these compounds are uptaken, they are metabolically transformated in vivo into 1-[2-dimethylamino-1-(4-hydroxyphenyl)-ethyl]-cyclohexanol that has neuropharmacological activity, by interrupting reuptake of 5-hydroxytryptamine (5-HT) and/or norepinephrine (NA), which is used for treating diseases associated with central nerve system, such as depression, etc. | 05-07-2009 |
| 20090124692 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR DECORPORATION OF RADIOACTIVE COMPOUNDS - A composition for removing a radioactive element or compound such as systemic transuranic compounds, from mammals comprises a pharmaceutical carrier and a decorporation agent comprising ester and amide derivatives of DTPA. A method of treating a mammal to remove systemic compounds utilizing the DTPA derivatives is also disclosed. | 05-14-2009 |
| 20090137669 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS - The present invention provides a creatine ester anti-inflammatory compound which may be received by animals and then metabolized into a biologically active form of creatine. The biologically active creatine inhibits the production of chemical mediators, released during an inflammatory response, which are important components in the inflammatory response and the inflammation and pain resulting from physical or chemical trauma to cells and tissue. | 05-28-2009 |
| 20090163591 | USE OF SUGAR PHOSPHATES, SUGAR PHOSPHATE ANALOGS, AMINO ACIDS AND/OR AMINO ACID ANALOGS FOR MODULATING THE GLUCOLYSIS-ENZYME COMPLEX, THE MALATE ASPARATE SHUTTLE AND/OR THE TRANSAMINASES - The invention relates to methods for the treatment of tumors and/or for immune suppression and/or sepsis by modulating the association of the glycolysis enzyme complex/M2-PK and/or by inhibition of transaminases and/or separation of the binding of the malate dehydrogenase to p36 comprising administering a pharmaceutical composition comprising a substance selected from the group consisting of amino acids, amino acid analogs, sugar phosphates, sugar phosphate analogs, and mixtures of said substances. | 06-25-2009 |
| 20090170941 | Pharmaceutical Compounds - Compounds or their salts of general formula (I): A-B—N(O) | 07-02-2009 |
| 20090192225 | Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use - Acyloxyalkyl carbamate prodrugs of α-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of α-amino acids and methods of using acyloxyalkyl carbamate prodrugs of α-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of α-amino acids suitable for oral administration using sustained release dosage forms are also disclosed. | 07-30-2009 |
| 20090203781 | N-N-Acyloxypropyl Lysine Methyl Ester-and N,N-Bis(N-Acyloxypropyl) Lysine Methyl Ester-Type Compounds and Use Thereof as Surface-Active Agents with an Antimicrobial Activity - The invention relates to novel compounds having an amphiphilic character (cationic, anionic, amphoteric and non-ionic), derivatives of n acyloxypropyl-type lysine amino acid according to general formula (I), which are intended to be used in the food, pharmaceutical and cosmetic industries as surface-active agents having a self-aggregating capacity and antimicrobial properties. Variations in activity are a function of the ionic nature of the final molecule, the number of fatty chains and the length thereof. The aforementioned products are prepared using a chemical synthesis method. The intermediate and final products are purified by means of liquid/liquid and liquid/solid extractions, crystallisations, cationic exchange chromatography and normal phase chromatography. | 08-13-2009 |
| 20090221703 | HIGH PENETRATION COMPOSITION AND USES THEREOF - The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for 4-aminophenol derivatives, which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate. | 09-03-2009 |
| 20090286878 | POLYOL DERIVED ANTI-MICROBIAL AGENTS AND COMPOSITIONS - Anti-microbial compositions are provided which comprise as an antimicrobial agent at least one compound derived from a select polyol containing at least 3 hydroxy groups wherein one or more, and often two or more, of the hydroxyls are derivitized to form certain ether, ester, carbonate or carbamate groups which groups may bear additional functionality. Novel antimicrobial compounds of this class are also provided. The compositions are effective against a variety of pathogens including fungi, Gram positive bacteria and Gram negative bacteria and are expected to have low human toxicity. Applications for the polyglycerol anti-microbial agents and compositions include those involving human and plant contact, such as cosmetics, hair care products, textiles and plant protections, as well as in applications with much less human contact, such as plastics, coatings, wood, paper and other materials of construction. | 11-19-2009 |
| 20090312419 | CREATINE - ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE - Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor. | 12-17-2009 |
| 20100056628 | Preservative compositions - Green and naturally derived biocides such as N | 03-04-2010 |
| 20100087527 | Curcumin Derivatives - The present invention is directed to a compound represented by Structural Formula (I): | 04-08-2010 |
| 20100093858 | USE OF L-CARNITINE OR OF ALKANOYL L-CARNITINES FOR THE PREPARATION OF A PHYSIOLOGICAL SUPPLEMENT OR MEDICAMENT FOR OPHTHALMIC USE IN THE FORM OF EYE DROPS - Use of L-carnitine and/or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an opthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases. | 04-15-2010 |
| 20100173993 | Controlled release biocidal salts - A controlled release biocidal salt of a first component comprises a cation of a N | 07-08-2010 |
| 20100292327 | TREATMENT OF ASPIRIN RESISTANCE WITH BETAINE AND/OR BETAINE ENRICHED MOLASSES - Use of glycine betaine as therapeutically active ingredient for the preparation of a medicament and/or a nutritional product and/or a dietary supplement for treating human resistant to a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, who suffers from a disease requiring the administration of a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, or who is at risk of suffering of said disease, whereby the medicament comprises an effective amount of glycine betaine for decreasing by at least 10%, advantageously at least 20% the resistance of said patient to said compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof | 11-18-2010 |
| 20100324137 | LAURIC ARGINATE AS A CONTACT ANTIMICROBIAL - A surface disinfecting composition includes a combination of lauric arginate ethyl ester in combination with EDTA, octenyl succinic acid, octanoic acid, glycolic acid, lactic acid, or combinations thereof. The aqueous solution can be used to disinfect a wide variety of surfaces including food processing and storage equipment, vegetables and fruits, as well as animal carcasses such as poultry. | 12-23-2010 |
| 20110028548 | BENEFICIAL EFFECTS OF INCREASING LOCAL BLOOD FLOW - The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and/or its derivatives alone, or optionally in conjunction with an adjunct such as theophylline. The transdermal delivery is effected, in certain embodiments through the means of a hostile biophysical environment, such as that created by a high ionic strength environment. Various pathological states caused by, or occurring in conjunction with, insufficient blood flow, can be treated using the systems and methods of the invention as described herein. In other embodiments, increased blood flow using the systems and methods of the invention may result in enhanced healing, for example, through greater availability of the constituents of the blood. Examples of conditions which may benefit from increased blood flow include, but are not limited to, erectile dysfunction, hair loss, female sexual dissatisfaction, sagging facial or other body tissue, peripheral vascular disease including claudication, neuropathy, skin ulcers, bone healing, wound healing, viral and bacterial infection, and skin grafting. | 02-03-2011 |
| 20110054023 | Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses - The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a cancer cell, tissue or tumor. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a tumor, increasing sensitivity of a tumor cell to radiation and/or chemotherapy, delaying tumor growth, inhibiting tumor blood vessel growth, inhibiting inflammatory responses in a cell through the use of compositions that prevent the nitrosylation of HIF-1, and methods for screening for new inhibitors of HIF-1 activiation. Additionally, the compositions disclosed herein relate to compositions that can be employed in, and are identified by, the disclosed methods. | 03-03-2011 |
| 20110086915 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy - The present invention relates to compounds being esters of 5-aminolevulinic acids or pharmaceutically acceptable salts thereof, including compounds of formula (I) R | 04-14-2011 |
| 20110105610 | Phospholipase A2 Inhibitors and their Use in Treating Neurological Injury and Disease - Phospholipase A | 05-05-2011 |
| 20110136905 | CRYSTALLINE TEGLICAR - The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same. | 06-09-2011 |
| 20110144203 | Use Of Cationic Surfactants As Sporicidal Agents - Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the treatment of objects which are infected with spores. The spores may originate from bacteria or fungi. | 06-16-2011 |
| 20110172306 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS - The present invention describes a method for providing creatine to an animal, which includes receiving a creatine ester by the animal. The creatine ester is suitable for being modified by the animal to form creatine. | 07-14-2011 |
| 20110218244 | CREATINE -ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE - Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor. | 09-08-2011 |
| 20110230558 | USE OF CATIONIC SURFACTANTS FOR THE INACTIVATION OF TOXINS - This invention relates to a use of a composition for the inactivation of toxins containing cationic surfactants such as ethyl-Nα-lauroyl-L-arginate HCI (LAE). It has been found that cationic surfactants such as ethyl-N | 09-22-2011 |
| 20110275714 | Use Of Cationic Surfactants As Acaricidal Agents - This invention relates to a use of a composition for protecting against mites and ticks containing cationic surfactants such as ethyl-Nα-lauroyl-L-arginate HCl (LAE). It has been found that cationic surfactants such as ethyl-N | 11-10-2011 |
| 20120095096 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES - The disclosure provides a series of 2-oxoamides based on dipeptides and pseudodipeptides, which were synthesized and their activities toward two human intracellular phospholipases A2 (GIVA CPLA | 04-19-2012 |
| 20120136054 | MATERIALS AND METHODS FOR MEASURING NITRIC OXIDE LEVELS IN BIOLOGICAL FLUIDS - The subject invention presides novel devices and methods for the measurement of nitric oxide in biological samples, including wound fluid samples. These advantageous devices and methods can be used for clinicians to monitor the wound's nitric oxide metabolism and/or response to treatment. | 05-31-2012 |
| 20120136055 | SEMI-SOLID COMPOSITIONS AND PHARMACEUTICAL PRODUCTS - This invention relates to semi-solid compositions and semi-solid pharmaceutical products for use in the photodynamic treatment (PDT) of cancer, pre-cancerous conditions and non-cancerous conditions in the female reproductive system, the anus and the penis, preferably for use in PDT of endometrial, cervical, vulvar, vaginal, anal and penile dysplasia and HPV infections of the uterus, cervix, the vulva, the vagina, the anus and the penis. The semi-solid compositions and pharmaceutical products comprise an active ingredient which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative of 5-ALA or pharmaceutically acceptable salts thereof. The invention relates further to methods of PDT of cancer, pre-cancerous conditions and non-cancerous conditions in the female reproductive system, the anus and the penis, wherein said semi-solid compositions and pharmaceutical products are used. | 05-31-2012 |
| 20120225942 | Synergistic Antimicrobial Agents - Synergistic antimicrobial compositions are provided by combining effective amounts of N | 09-06-2012 |
| 20120289597 | NITRIC OXIDE AMINO ACID ESTERS FOR THE TREATMENT OF CHRONIC PAIN - There is provided a topical composition and a method for treating or alleviating pain in a patient in need thereof. The topical composition contain amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof and a topical analgesic compound. | 11-15-2012 |
| 20130231389 | Delivery Of Preservatives By Food Packaging - A composition comprising a polymeric material and a preservative combination of 1) a preservative component selected from the salts of N | 09-05-2013 |
| 20130289111 | Methods Of Preservation - This invention discloses a method of preservation of a food product comprising the step of adding 1) a first component comprising between 10 ppm and 1% of a biocidal salt of N | 10-31-2013 |
| 20130338227 | Green Glycine Betaine Derivative Compounds And Compositions Containing Same - Multifunctional green (eco-friendly) and antimicrobial compositions are described containing cationic glycine betaine esters and/or cationic glycine betaine amides. Particular glycine betaine esters and amides are alkyl(ene) betainate methane sulfonates and betainyl amino alkyl(ene) methane sulfonates. The glycine betaine components are cationic, have a hydrophobic group attached to a carboxylate group through an ester or amide linkage, and are derived from a natural source, such as sugar beets. The glycine betaine esters and amides serve as cationic surfactants which have effective antimicrobial activity. The surfactant compositions are effective as crude mixtures or semi-purified mixtures or purified surfactant compounds of glycine betaine components. The addition of sodium chloride or potassium chloride or magnesium chloride or natural gum or polysaccharide to compositions containing the cationic glycine betaine ester and/or glycine betaine amide derivatives serves to thicken or gel the composition. | 12-19-2013 |
| 20140309302 | Antimicrobial Preservative Compositions for Personal Care Products - A personal product antimicrobial preservative composition for preservation of topical personal care formulations is provided and includes [A] one or more undecylenic acid derivatives depicted by Formula (I), | 10-16-2014 |
| 20150031761 | USE OF 5-AMINOLEVULINIC ACID AND DERIVATIVES IN A SOLID FORM FOR PHOTODYNAMIC TREATMENT AND DIAGNOSIS - The present invention relates to the use of a photosensitiser which is 5-ALA or a precursor or derivative thereof (e.g. an ALA ester), in the manufacture of a pharmaceutical product for use in the photodynamic treatment or diagnosis of cancer, an infection associated with cancer, or in the treatment or diagnosis of a non-cancerous condition, wherein said pharmaceutical product is in the form of a solid. The invention also relates to solid pharmaceutical products for use in such methods, e.g. suppositories, pessaries, tablets, pellets and capsules which comprise 5-ALA or a precursor or derivative thereof (e.g. an ALA ester) and at least one pharmaceutically acceptable carrier or excipient. Such products are particularly suitable for use in the photodynamic treatment or diagnosis of cancerous or non-cancerous conditions in the lower part of the gastrointestinal system or in the female reproductive system, e.g. in the treatment or diagnosis of colorectal cancer or cervical cancer. | 01-29-2015 |
| 20150073051 | CATIONIC ANTIMICROBIAL HANDWASH - An antimicrobial composition is provided that includes from about 0.1 to about 2 wt. % of a cationic antimicrobial agent selected from the group consisting of lauric arginate and benzalkonium chloride, based upon the total weight of the antimicrobial composition; from about 1 to about 10 wt. % of two or more nonionic surfactants selected from the group consisting of glucoside alkyl ethers and poloxamers, based upon a total weight of the antimicrobial composition; from about 0.1 to about 5 wt. % of an amine oxide, based upon the total weight of the antimicrobial composition; and one or more preservatives selected from phenoxyethanol, ethylhexyl glycerin, hexylene glycol, caprylyl glycol, and mixtures thereof. | 03-12-2015 |
| 20150080466 | DIPHENYL UREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS - The present invention relates to diphenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2. | 03-19-2015 |
| 20150299112 | METHOD FOR PREPARING CREATINE FATTY ESTERS, CREATINE FATTY ESTERS THUS PREPARED AND USES THEREOF - The present invention concerns a method for preparing a creatine fatty ester or derivative thereof comprising at least one step consisting in reacting a diprotected creatinine with a molecule bearing at least one alcohol functional group and of formula R′—OH in which R′ represents a hydrocarbon radical containing at least 4 carbon atoms. The present invention also concerns particular creatine fatty esters or derivative thereof and medical uses thereof. | 10-22-2015 |
| 20160143874 | HISTONE DEACETYLASE INHIBITORS - In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for exmaple. The present invention also provides methods for preparing compounds of the invention and intermediates thereto. | 05-26-2016 |
| 20180020661 | POWDER FORMULATION CONTAINING INSECT REPELLENT | 01-25-2018 |
